Kowa Announces The Efficacy And Safety Of A Novel Rho Kinase Inhibitor (K-115) In The Treatment Of Glaucoma In ARVO 2011
Kowa Company Ltd, (Headquarters: Nagoya, Japan, President & CEO: Yoshihiro Miwa, "Kowa") today announced the results of two clinical studies and a non-clinical study of a drug candidate for glaucoma and ocular hypertension (K-115). The results were presented as three posters at The Association for Research in Vision and Ophthalmology (ARVO) 2011 meeting in Fort Lauderdale, Florida, USA...